Cure8
Health-related quality of life after diagnosis of ulcerative colitis and Crohn’s disease: 3-year trajectories and factors associated with clinically meaningful improvement (the IBSEN III cohort)
Inflammatory Bowel Diseases

Cure8 research brief

Health-related quality of life after diagnosis of ulcerative colitis and Crohn’s disease: 3-year trajectories and factors associated with clinically meaningful improvement (the IBSEN III cohort)

2 min read
Mental health and quality of life Fatigue Remission Clinical study Adult patients Clinicians Researchers Newly Diagnosed

Why This Matters

This study follows people from diagnosis and shows that about half achieve clinically meaningful improvements in quality of life by 3 years, but many remain below general population norms.

It highlights that symptom control and psychosocial factors—depression, fatigue, IBS-like symptoms—are important determinants of patient-reported recovery.

Who Should Pay Attention

Newly diagnosed adult IBD patients; clinicians treating early UC or Crohn’s disease; researchers focused on HRQoL, patient-reported outcomes, and psychosocial factors.

Study Snapshot

Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract

What To Know

The study followed adults with new-onset UC or CD using the IBDQ and SF-36 at diagnosis, 1 year, and 3 years. Around half of patients reached established minimal clinically important difference thresholds by follow-up, but average HRQoL scores stayed below Norwegian population norms.

Achieving symptomatic remission was consistently associated with higher odds of meaningful HRQoL improvement. By contrast, depressive symptoms, substantial fatigue, and IBS-like symptoms were associated with lower odds of improvement.

The authors report that endoscopic remission, use of biologic therapy, and bowel surgery in the first year were not significantly linked to clinically meaningful HRQoL gains in their analyses.

Keep In Mind

Summary is based on the journal abstract (structured content depth: abstract). The study reports associations from a population-based cohort; it does not by itself prove causation. Full methods and subgroup details are in the article.

Source Details

Review the original publication for the complete reporting, methods, and context.

Read Original Source
Research paper Evidence type derived from source or registry metadata.
PublicationInflammatory Bowel Diseases
PublisherOxford University Press (OUP)
AuthorsBjorn Christian Olsen, Milada Hagen, Randi Opheim +18 more
Study typeJournal Article
Indexed viaCrossref
Source typeResearch paper
PublishedOct 14, 2026, 12:00 AM
Content availableJournal abstract

Funding disclosed by the source: Telemark Hospital Trust, award 3092.03; Takeda Pharmaceuticals, Pfizer; Ferring Pharmaceuticals; Tillotts Pharma; the Dam Foundation; the South-Eastern Health Authorities

This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.

Related Reading

Browse latest news →